Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors
2008

Cost-Effectiveness of Joint Pain Treatments for Osteoarthritis

Sample size: 1000 publication 10 minutes Evidence: high

Author Information

Author(s): Iris Contreras-Hernández, Joaquín F Mould-Quevedo, Rubén Torres-González, María Victoria Goycochea-Robles, Reyna Lizette Pacheco-Domínguez, Sergio Sánchez-García, Juan Manuel Mejía-Aranguré, Juan Garduño-Espinosa

Primary Institution: Instituto Mexicano del Seguro Social

Hypothesis

Which pharmacological treatment is the most cost-effective for joint pain in osteoarthritis patients?

Conclusion

Celecoxib is the most cost-effective treatment option for knee and/or hip osteoarthritis.

Supporting Evidence

  • Celecoxib had the lowest cost-effectiveness ratio at $17.5 pesos/patient.
  • Celecoxib was found to be more effective than nonselective NSAIDs and acetaminophen.
  • The study included a systematic review of literature to support its findings.

Takeaway

This study found that celecoxib is the best medicine for treating joint pain from arthritis because it works well and costs less overall.

Methodology

A cost-effectiveness assessment was conducted using a decision tree model and systematic literature review.

Potential Biases

Publication bias may exist as only published articles were included in the systematic review.

Limitations

The study may not reflect results for the Mexican population due to local factors affecting clinical response.

Participant Demographics

Patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social.

Digital Object Identifier (DOI)

10.1186/1478-7547-6-21

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication